ArticleDiscover oncology2025
Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lysosomes have a tight connection to cancer and can eliminate cancer cells. The dismal prognosis of acute myeloid leukemia (AML) patients may thus be improved by a thorough examination of the function of lysosome-related genes (LRGs). By using a variety of machine learning methods including random forest approach, LASSO-COX regression, and extreme gradient boosting (XGBoost), we create a prognostic six-LRGs-related signature (HPS1, BCAN, SLC2A8, DOC2A, CHMP4C, and SLC29A3), which categorized AML patients into two groups with significant survival and tumor microenvironment (TME) differences. Data from the ICGC and TARGET cohorts were used as test cohorts for the validation of the prognostic LRGs-related signature. We also discovered that chemotherapeutic susceptibility was connected to the LRGs-related signature. Finally, we evaluated gene expression levels in the LRGs-related signature between normal and AML samples and confirmed the elevation of CHMP4C expression in 90 clinical samples. In summary, a six-LRGs-related signature was developed to predict the prognosis of AML patients, and more research is necessary to determine whether this signature has therapeutic promise as an anti-AML target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.